title: A new treatment regimen for rosacea: onabotulinumtoxinA.
abstract: Rosacea is a cutaneous condition with several clinical subtypes that are commonly seen in daily medical practice. There are many different treatment modalities for each of the physical findings associated with this disease, and all have varying results. As the use of onabotulinumtoxinA rises, its benefit in the treatment of a growing number of medical diseases increases. The authors report anecdotal evidence of patients with rosacea experiencing improved symptoms of erythema and flushing after treatment with intradermal, microdroplets of onabotulinumtoxinA. There were no adverse events reported for any of the treatments. The mechanism of action through a likely neurogenic component to vascular dysfunction, inflammation, and hypersebaceous activity is reviewed.
authors: Department of Otolaryngology, University of Illinois, Chicago, IL, USA. sdayan@drdayan.com
authors: Steven H
authors: SH
authors: Dayan
authors: Rachel N
authors: RN
authors: Pritzker
authors: John P
authors: JP
authors: Arkins
mesh_terms: D019274:Botulinum Toxins, Type A / Q000008:administration & dosage / Q000627:therapeutic use*; D004890:Erythema / Q000188:drug therapy / Q000209:etiology; D005260:Female; D005483:Flushing; D006801:Humans; D007271:Injections, Intradermal; D008845:Microinjections; D008875:Middle Aged; D012393:Rosacea / Q000188:drug therapy* / Q000473:pathology; D012627:Sebaceous Glands / Q000187:drug effects; D012867:Skin / Q000473:pathology; D013546:Sweating; D013684:Telangiectasis / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D019274:Botulinum Toxins, Type A